ClinicalTrials.gg
RecruitingNCT01561157Updated May 15, 2026

Longitudinal Study of the Porphyrias

An observational study in Acute Porphyrias and Cutaneous Porphyrias, sponsored by The American Porphyrias Expert Collaborative. Recruiting at 16 sites in United States. Open to participants aged 1 Minute and older. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by The American Porphyrias Expert Collaborative · Observational

How we know

From the registry’s dates

  • Started Nov 2010; still recruiting 16 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,500
Ages
1 Minute and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Porphyria, Acute Intermittent with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Porphyria, Acute Intermittent · United States.

Started
2010
the only one that year
Observational
6 of 12
2 open now
Registered
2nd of 12
by date
Lead sponsor
1 of 12
The American Porphyrias Expert Collaborative

Among the 12 studies in Porphyria, Acute Intermittent with a site in United States, this one is the only one that started in 2010, is one of 6 observational ones, and was the 2nd registered.

Porphyria, Acute Intermittent

21 studies on the registry are indexed under Porphyria, Acute Intermittent; 3 are open to participants now.

Browse Porphyria, Acute Intermittent studies →

Open to participants now

2 of the 12 studies in Porphyria, Acute Intermittent with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Porphyria, Acute Intermittent studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 1 Minute and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Porphyria, Acute Intermittent with a site in United States, or all of them as a file.
02

Study summary

The objective of this protocol is to conduct a longitudinal multidisciplinary investigation of the human porphyrias including the natural history, morbidity, pregnancy outcomes, and mortality in people with these disorders.

Read the detailed description

The porphyrias are a group of rare metabolic diseases that may present in childhood or adult life and are due to deficiencies of enzymes in the heme biosynthetic pathway. The most common manifestations are related to accumulation of intermediates in the pathway and usually occur as acute neurological attacks, or cutaneous photosensitivity. Multiple mutations have been identified in each of the porphyrias. The risk of disability or death from these disorders is significant, in part because diagnosis is often delayed due to lack of adoption of diagnostic testing in clinical practice. Moreover, the natural history of these disorders is not well described and it is not known what determines differences in outcomes. New therapies are needed. For existing therapies, high-quality evidence on short and long term efficacy and safety is generally lacking. Therefore, the purpose of this long-term follow-up study of a large group of patients with the various porphyrias is to provide a better understanding of the natural history of these disorders, as affected by available therapies, and to aid in developing new forms of treatment.

The Office of Rare Diseases (ORD) of the National Institutes of Health (NIH) established a Rare Diseases Clinical Research Network (RDCRN) in collaboration with other NIH Institutes and currently has funded several rare diseases clinical research consortia and one Data Management and Coordinating Center. The Porphyrias Consortium was created as part of the RDCRN, to study the human porphyrias. The Porphyrias Consortium is a consortium of the academic institutions listed in the participating institutions table. All Centers in the Porphyrias Consortium are participating in the Longitudinal Study of the Porphyrias. Additional centers may be added if funding is available.

The initial objective of this protocol is to assemble a well-documented group of patients with confirmed diagnoses of specific porphyrias for clinical, biochemical, and genetic studies. The long-term objective is to conduct a longitudinal investigation of the natural history, complications, and therapeutic outcomes in people with acute and cutaneous porphyria.

03

Conditions studied

  • Acute Porphyrias
  • Cutaneous Porphyrias

Keywords

  • porphyria
  • acute intermittent
  • coproporphyria
  • variegate
  • erythropoietic
  • protoporphyria
  • hepatoerythropoietic
  • cutanea tarda
  • AIP
  • HCP
  • VP
  • ADP
  • ALAD
  • PCT
  • HEP
  • CEP
  • EPP
  • XLP
  • homozygous dominant
  • acute hepatic
  • AHP
04

Who can participate

Ages eligible
1 Minute and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects will be recruited from the following resources:

  1. Patients followed by one of the Investigators
  2. United Porphyrias Association (UPA)
  3. Non-study Physician referrals
  4. Self-referrals, including family members of individuals diagnosed with Porphyria (proband) and other individuals who may have heard about the study from other subjects or prospective subjects.
  5. Medical Records Review

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals with a documented diagnosis of a porphyria.
  • For each type of porphyria, the inclusion criteria are based on

    • Biochemical findings, as documented by laboratory reports (or copies) of porphyria-specific testing performed after 1980 (Absolute values are preferred for diagnostic biochemical thresholds. Fold increases in comparison to an upper (or lower) limit of normal ( or LLN) are also acceptable, but are complicated by considerable variation between laboratories in normal limits. Equivocal biochemical measurements may require confirmation by a consortium reference laboratory;)
    • molecular findings documenting the identification of a mutation in a porphyria-related gene.
  • In addition, an individual or a parent or guardian must be willing to give written or assent, as appropriate.
  • Provision is made for enrolling relatives who may not have symptoms but have biochemical or molecular documentation of a porphyria, or in the case of recessive disorders carry a disease-related mutation.

Exclusion criteria

Exclusion Criteria:

  • Cases with elevations of porphyrins in urine, plasma or erythrocytes due to other diseases (i.e. secondary porphyrinuria or porphyrinemia), such as liver and bone marrow diseases;
  • Patients with a prior diagnosis of porphyria that cannot be documented by review of existing medical records or repeat biochemical or DNA testing.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,500 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Acute Intermittent Porphyria (AIP)

    Patients with a documented diagnosis of AIP

  • Hereditary Coproporphyria (HCP)

    Patients with a documented diagnosis of HCP

  • Variegate Porphyria (VP)

    Patients with a documented diagnosis of VP

  • Congenital Erythropoietic Porphyria (CEP)

    Patients with a documented diagnosis of CEP

  • Hepatoerythropoietic Porphyria (HEP)

    Patients with a documented diagnosis of HEP

  • Porphyria Cutanea Tarda (PCT)

    Patients with a documented diagnosis of PCT

  • Erythropoietic Protoporphyria (EPP)

    Patients with a documented diagnosis of EPP

  • X-Linked Protoporphyria (XLP)

    Patients with a documented diagnosis of XLP

  • Aminolevulinate-Dehydratase Deficiency Porphyria (ALAD, ADP)

    Patients with a documented diagnosis of ALAD, ADP

  • Homozygous Dominant Acute Hepatic Porphyria

    Patients with a documented diagnosis of Homozygous Dominant AHP

06

What researchers measure

Primary outcomes

  1. clinical analysis

    To develop disease severity scores to describe the combined frequency and severity of disease manifestations, utilizing linear mixed effects models \& stratification by age of onset.

    Time frame: baseline

  2. Laboratory analysis

    To evaluate porphyrin and porphyrin precursor levels alone or by genotype and porphyria subtype

    Time frame: baseline

Secondary outcomes

  1. Relationship between disease severity and biomarkers

    To develop longitudinal models that relate, for example, porphyrin and porphyrin precursor levels alone or in concert with age, genotype and other features to the disease manifestation frequency.

    Time frame: baseline

  2. Effectiveness and tolerability of currently used and new therapies for the human porphyrias

    Qualitative evaluation, using self-reporting questionnaires and clinical findings, and quantitative evaluation, using laboratory measures of organ function and porphyrin levels, to evaluate the effectiveness of therapies.

    Time frame: baseline

07

Study locations

11 of 16 sites recruiting
08

References and documents

Publications

  • Balwani M, Naik H, Anderson KE, Bissell DM, Bloomer J, Bonkovsky HL, Phillips JD, Overbey JR, Wang B, Singal AK, Liu LU, Desnick RJ. Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria. JAMA Dermatol. 2017 Aug 1;153(8):789-796. doi: 10.1001/jamadermatol.2017.1557. PubMed 28614581 ↗
  • Saberi B, Naik H, Overbey JR, Erwin AL, Anderson KE, Bissell DM, Bonkovsky HL, Phillips JD, Wang B, K Singal A, M McGuire B, Desnick RJ, Balwani M. Hepatocellular Carcinoma in Acute Hepatic Porphyrias: Results from the Longitudinal Study of the U.S. Porphyrias Consortium. Hepatology. 2021 May;73(5):1736-1746. doi: 10.1002/hep.31460. Epub 2020 Dec 11. PubMed 32681675 ↗
  • Levy C, Naik H, Overbey J, Hedstrom K, Wang K, McDonough C, Freeman M, Keel SB, Erwin AL, Dickey AK, Leaf RK, Quigley J, Mazepa M, Wang B, Phillips J, Parker C, McGuire B, Kazamel M, Bonkovsky H, Rudnick S, Anderson KE, Moghe A, Thapar M, Saberi B, Wheeden K, Desnick R, Balwani M; Porphyrias Consortium of the Rare Diseases Clinical Research Network. Liver involvement in a large cohort of patients with erythropoietic protoporphyria or X-linked protoporphyria. Hepatol Commun. 2025 Feb 19;9(3):e0657. doi: 10.1097/HC9.0000000000000657. eCollection 2025 Mar 1. PubMed 39969427 ↗
  • Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, Phillips JD, Naik H, Peter I, Baillargeon G, Bossi K, Gandolfo L, Light C, Bishop D, Desnick RJ. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014 Dec;127(12):1233-41. doi: 10.1016/j.amjmed.2014.06.036. Epub 2014 Jul 10. PubMed 25016127 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2010 (actual). Primary completion is estimated for Jun 2030, 235 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2012
First posted
Mar 22, 2012
StartActual
Nov 1, 2010
Primary completionEst.
Jun 30, 2030
CompletionEst.
Jun 30, 2030
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01561157
Lead sponsor
The American Porphyrias Expert Collaborative
Responsible party
Hetanshi Naik (Associate Professor, Stanford University) — Principal investigator
First posted
Mar 22, 2012
Start date
Nov 1, 2010
Primary completion
Jun 30, 2030 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
May 15, 2026

Study contacts

Kristen P Wheeden, DrPH
Contact
kristen@porphyria.org
301-461-9889
Hetanshi Naik, PhD
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion